Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bromfenac
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Launches Bromfenac Ophthalmic Solution, 0.075% in US
Details : BromSite-Generic (bromfenac) acts by inhibiting Cox-1 and 2. It is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.
Product Name : BromSite-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : Bromfenac
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromfenac
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Bausch & Lomb Incorporated | Churchhill Communications | Statistics & Data Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2019
Lead Product(s) : Bromfenac
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Bausch & Lomb Incorporated | Churchhill Communications | Statistics & Data Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromfenac
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2013
Lead Product(s) : Bromfenac
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromfenac
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2012
Lead Product(s) : Bromfenac
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2011
Lead Product(s) : Bromfenac
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2011
Lead Product(s) : Bromfenac
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Bausch & Lomb Incorporated
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromfenac
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2010
Lead Product(s) : Bromfenac
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable